Dextran Or Derivative Patents (Class 514/59)
-
Publication number: 20130034516Abstract: The subject of the invention is the use of cationically modified polysaccharides, except for chitosan, for direct neutralization of heparin in blood and physiological fluids in a mammal. Cationic modification of the polysaccharides is achieved using compound containing cationic ammonium groups and/or the polysaccharides are grafted with a polymer containing amine and/or ammonium groups.Type: ApplicationFiled: April 20, 2011Publication date: February 7, 2013Applicant: UNIWERSYTET JAGIELLONSKIInventors: Maria Nowakowska, Krzysztof Szczubialka, Kamil Kaminski
-
Patent number: 8367640Abstract: The invention relates to a complex consisted of a polysaccharide and an HBP, said polysaccharide being consisted from glycoside bonds of (1,6) and/or (1,4) and/or (1,3) and/or (1,2) type and functionalized with at least one salifiable or salified tryptophan derivative. The invention also relates to a pharmaceutical composition comprising a complex according to the invention and to the use of a polysaccharide consisted of glycoside bonds of (1,6) and/or (1,4) and/or (1,3) and/or (1,2) type and functionalized with at least one salifiable or salified tryptophan derivative, for the preparation of a pharmaceutical formulation of stable HBPs.Type: GrantFiled: September 28, 2009Date of Patent: February 5, 2013Assignee: AdociaInventors: Olivier Soula, Remi Soula, Martin Gaudier, Gerard Soula
-
Publication number: 20130017198Abstract: A novel mechanism by which after-depolarization occurs in cardiac myocytes has been discovered, involving calcium influx through the arachidonate-regulated calcium channel (ARCC) and the store-operated calcium channel (SOCC). Because after-depolarization of the myocyte is a major cause of cardiac arrhythmia, this discovery provides new approaches for treating and preventing heart disease. By down-regulating the activity of the ARCC or the SOCC, after-depolarization can be decreased and cardiac arrhythmia can be prevented, reduced, or eliminated. This can be accomplished using pharmaceuticals containing inhibitors of the ARCC or the SOCC, or by genetically modifying cells to reduce ARCC or SOCC activity. In addition, assays are disclosed using the ARCC or SOCC to discover potential anti-arrhythmic agents. Cellular and animal models of arrhythmia are disclosed in which the activity of the ARCC or SOCC is increased to promote after-depolarization and induce arrhythmia.Type: ApplicationFiled: March 25, 2011Publication date: January 17, 2013Applicant: THE UAB RESEARCH FOUNDATIONInventors: Paul Wolkowicz, Jian Huang
-
Publication number: 20130011337Abstract: To provide a therapeutic agent and a diagnostic agent for mitochondrial dysfunction brain diseases including cerebral infarction as a representative. A therapeutic agent for a mitochondrial dysfunction brain disease, which comprises (A) ?-aminolevulinic acid represented by the formula (1), a derivative thereof, or a salt thereof and (B) an iron compound in combination. R2R1NCH2COCH2CH2COR3 ??(1) wherein R1 and R2 each independently represents a hydrogen atom, an alkyl group, an acyl group, an alkoxycarbonyl group, an aryl group, or an aralkyl group; and R3 represents a hydroxy group, an alkoxy group, an acyloxy group, an alkoxycarbonyloxy group, an aryloxy group, an aralkyloxy group, or an amino group.Type: ApplicationFiled: September 13, 2012Publication date: January 10, 2013Applicant: SBI PHARMACEUTICALS CO., LTD.Inventors: Toshihiko KUROIWA, Yoshinaga KAJIMOTO, Takahiro MASUBUCHI, Masahiro ISHIZUKA, Tohru TANAKA
-
Publication number: 20120328585Abstract: The present invention is directed to a novel method for increasing the production of acetate, decreasing the production of butyrate, increasing the population and species of beneficial bacteria and slowing the rate of fermentation of prebiotics within the gut of a formula-fed infant. The method comprises administration of a therapeutically effective amount of PDX to the infant.Type: ApplicationFiled: September 4, 2012Publication date: December 27, 2012Inventors: Bryon W. Petschow, Robert J. McMahon, Glenn R. Gibson, Robert A. Rastall, Renia Gemmell, Maria Saarela, Anna-Marja Aura
-
Patent number: 8338140Abstract: The present invention concerns methods and compositions for delivery of therapeutic agents to target cells, tissues or organisms. In preferred embodiments, the therapeutic agents are delivered in the form of therapeutic-loaded polymers that may comprise many copies of one or more therapeutic agents. In more preferred embodiments, the polymer may be conjugated to a peptide moiety that contains one or more haptens, such as HSG. The agent-polymer-peptide complex may be delivered to target cells by, for example, a pre-targeting technique utilizing bispecific or multispecific antibodies or fragments, having at least one binding arm that recognizes the hapten and at least a second binding arm that binds specifically to a disease or pathogen associated antigen, such as a tumor associated antigen. Methods for synthesizing and using such therapeutic-loaded polymers and their conjugates are provided.Type: GrantFiled: September 27, 2011Date of Patent: December 25, 2012Assignee: Immunomedics, Inc.Inventors: Serengulam V. Govindan, Sung-Ju Moon, David M. Goldenberg, Chien-Hsing Chang
-
Publication number: 20120321584Abstract: An inhibiting heart failure disease pharmaceutical composition is provided. The pharmaceutical composition includes: an effective amount of a KMUP-3 amine salt of formula (I); wherein RX contains a carboxylic group donated from one selected from a group consisting of a sodium carboxyl methylcellulose (sodium CMC), a ?-polyglutamic acid derivative, and co-polymer salt; RX? is an anion form of the carboxylic group; and a pharmaceutically accepted carrier.Type: ApplicationFiled: January 23, 2012Publication date: December 20, 2012Applicant: KAOHSIUNG MEDICAL UNIVERSITYInventor: Ing-Jun Chen
-
Patent number: 8333962Abstract: A controlled release multidrug formulation for improving locomotor recovery after spinal cord injury comprising: (a) a first composition comprising a first bioactive agent, encapsulated within a first polymeric particle; (b) a second composition comprising a second bioactive agent, encapsulated within a second polymeric particle, wherein the second polymeric particle is encapsulated within the first polymeric particle; and (c) a third composition comprising a third bioactive agent, encapsulated within either the first or the second polymeric particle, wherein the second composition is released subsequently to the release of the first composition, and wherein the first bioactive agent is a neurotrophic factor, the second bioactive agent is a collagen synthesis inhibitor, and the third bioactive agent is selected from the group consisting of cyclic AMP (cAMP), an adenylate cyclase activator and a Rho inhibitor.Type: GrantFiled: August 27, 2009Date of Patent: December 18, 2012Assignee: National Health Research InstitutesInventors: Yu-Chao Wang, Yi-Ting Wu, Chung-Shi Yang
-
Publication number: 20120289469Abstract: Methods and compositions for maintaining an active agent in an intra-articular space are disclosed. Methods of delivering the compositions to an intra-articular space and methods of making the compositions also are disclosed. The compositions comprise an active agent and a polymer comprising at least one cationic group. A fluid including the composition may be injected into an intra-articular space in a human or animal whereby the composition associates with endogenous material in the intra-articular space. In some embodiments, the fluid further comprises a poorly aqueous soluble polymer.Type: ApplicationFiled: May 10, 2012Publication date: November 15, 2012Inventors: Michael M. Morgen, Warren K. Miller
-
Publication number: 20120282220Abstract: Methods and compositions for reducing fibrosis and cirrhosis are provided in which an effective dose of an admixture of a polysaccharide compound and, for example, a compound selected from the group consisting of antibodies specific to intracellular or cell-surface: (i) beta-PDGF receptors; (ii) synaptophysin; (iii) zvegf3; (iv) CCR1 receptors; (v) connective tissue growth factor; (vi) alpha 1-smooth muscle actin; (vii) matrix metalloproteinases MMP 2 and MMP9; (viii) matrix metalloproteinase inhibitors TIMP1 and TMP2; (ix) integrins; (x) TFG-?1; (xi) endothelin receptor antagonists; and (xii) collagen synthesis and degradation modulating compounds; (xiii) actin synthesis and degradation modulating compounds; and (xiv) tyrosine kinases is administered to an animal in order to treat fibrosis.Type: ApplicationFiled: July 17, 2012Publication date: November 8, 2012Applicant: Galectin TherapeuticsInventors: David Platt, Eliezer Zomer, Anatole Klyosov
-
Publication number: 20120251482Abstract: The synthesized piperazium salt of KMUPs disclosed in the present invention is characterized by presented pharmaceutics having functions to improve 5-HT function and eNOS expression of KMUPS in lung diseases, such as proliferation, obliteration, pulmonary artery hypertension. The pharmaceutical composition for inhibiting monocrotaline (MCT)-induced proliferation of pulmonary artery includes an effective amount of a complex salt of formula (I): wherein R2 and R4 are each selected independently from the group consisting of a C1˜C5 alkoxy group, a hydrogen, a nitro group, and a halogen atom; RX contains a carboxylic group donated from one selected from a group consisting of a Statin, a Co-polymer, a poly-?-polyglutamic acid (?-PGA) derivative and sodium CMC; and ?RX substituent is an anion of the carboxylic group carrying a negative charge; and a pharmaceutically accepted carrier.Type: ApplicationFiled: September 19, 2011Publication date: October 4, 2012Applicant: KAOHSIUNG MEDICAL UNIVERSITYInventor: Ing-Jun Chen
-
Patent number: 8247391Abstract: The present invention relates to a gel composition, comprising first and second gel-forming moieties which bind reversibly to one another to form a gel. The binding of the moieties is sensitive to the level of an analyte, and either or both of the gel-forming moieties are attached to cross-linked particulate entities such that the interstices between the entities allow gel-sol and sol-gel transformation, and yet are not so small that the analyte cannot diffuse therethrough. The invention also provides drug delivery systems and sensors for detecting an analyte utilizing such a gel.Type: GrantFiled: July 10, 2002Date of Patent: August 21, 2012Assignee: De Montfort UniversityInventor: Margaret Taylor
-
Publication number: 20120207791Abstract: The present invention relates to immobilized biologically active entities having heparin cofactor II binding activity.Type: ApplicationFiled: August 11, 2011Publication date: August 16, 2012Inventors: Robert L. Cleek, Michael D. Daly, Krzysztof R. Pietrzak
-
Patent number: 8242097Abstract: The present disclosure relates to the cosmetic use of grafted polysaccharide compounds comprising at least one non-polymer siloxane graft that may be obtained by reacting a polysaccharide and a siloxane compound corresponding to formula (I), such as for the cosmetic treatment of keratin materials. The disclosure also relates to compositions comprising the grafted polysaccharide compounds in a cosmetically acceptable medium, and also to certain novel grafted polysaccharide compounds comprising at least one non-polymer siloxane graft.Type: GrantFiled: August 18, 2005Date of Patent: August 14, 2012Assignee: L'Oreal S.A.Inventor: Michel Philippe
-
Publication number: 20120195976Abstract: The present invention relates to the treatment of disorders using heme oxygenase-1 and heme degradation products.Type: ApplicationFiled: December 9, 2011Publication date: August 2, 2012Inventors: Fritz H. Bach, Pascal O. Berberat, Simon C. Robson
-
Publication number: 20120177600Abstract: A composition capable of attenuating platelet hyperactivation and associated methods for administering the same to a subject, the composition comprising an aqueous solution containing from about 0.1% to about 7.0% by weight of a glycosaminoglycan and from about 1.0% to about 32% by weight of a neutral polysaccharide.Type: ApplicationFiled: September 21, 2010Publication date: July 12, 2012Inventors: Peter Byron Buckley, Konrad Messmer, Mark William Phillips
-
Publication number: 20120164183Abstract: The present invention generally concerns the detection and/or treatment of aneurysm in a non-invasive manner. In particular cases, the invention concerns methods and compositions for localizing a labeled composition to the site of an aneurysm for its detection and, in further cases, treatment of the aneurysm. In specific cases, the composition targets a subendothelial component of the aneurysmal wall, such as a smooth muscle cell exposed at the luminal surface of the vessel. In further specific cases, the composition targets an integrin receptor or laminin.Type: ApplicationFiled: November 23, 2008Publication date: June 28, 2012Inventors: Lionel C. Sevrain, Sylvie Y. Verdier- Sevrain
-
Publication number: 20120148523Abstract: A hydrogel tissue adhesive formed by reacting an aldehyde-functionalized polysaccharide containing pendant aldehyde groups with a water-dispersible, multi-arm amine is described. The hydrogel may be useful as a tissue adhesive or sealant for medical applications that require a more rapid degradation time, such as the prevention of undesired tissue-to tissue adhesions resulting from trauma or surgery.Type: ApplicationFiled: June 30, 2010Publication date: June 14, 2012Applicant: Actamax Surgical Materials LLCInventors: Helen S.M. Lu, Steven W. Shuey
-
Publication number: 20120128763Abstract: A formulation has been developed for treatment of the symptoms of dry eye which incorporates the natural product jojoba wax, or components thereof, to enhance the spreading of the artificial tear and eyedrop as well as stabilize the eyedrop. The improved performance of the jojoba wax supplemented tear relieves irritation and discomfort as well as sharpens the blurred vision.Type: ApplicationFiled: February 2, 2012Publication date: May 24, 2012Inventor: Steven Maskin
-
Publication number: 20120116215Abstract: A method for treating a site within a patient from which tissue has been removed includes providing at least one press-formed marker body formed of polysaccharide and a suitable binder; and placing the at least one of the press-formed marker body within the site where tissue has been removed so as to provide hemostasis therein.Type: ApplicationFiled: November 21, 2011Publication date: May 10, 2012Inventors: Michael L. Jones, Paul Lubock
-
Publication number: 20120114724Abstract: The present disclosure is directed to method of preparing an antimicrobial agent comprising heating a dialdehyde polysaccharide. The method comprises subjecting a dialdehyde polysaccharide, such as a dialdehyde starch or a dialdehyde cellulose, to heating and/or sonication for a period of time. Also provided herein is an antimicrobial composition comprising the prepared dialdehyde polysaccharide. The antimicrobial composition is effective at killing microbial agents such as viruses and bacteria within a short period of time.Type: ApplicationFiled: November 8, 2010Publication date: May 10, 2012Applicant: UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC.Inventors: Ronald Howard Baney, Samuel Ralph Farrah, Le Song
-
Publication number: 20120109044Abstract: A method for direct therapeutic treatment of myocardial tissue in a localized region of a heart having a pathological condition. The method includes identifying a target region of the myocardium and applying material directly and substantially only to at least a portion of the myocardial tissue of the target region. The material applied results in a physically modification the mechanical properties, including stiffness, of said tissue. Various devices and modes of practicing the method are disclosed for stiffening, restraining and constraining myocardial tissue for the treatment of conditions including myocardial infarction or mitral valve regurgitation.Type: ApplicationFiled: May 26, 2011Publication date: May 3, 2012Applicant: CORMEND TECHNOLOGIES, LLCInventors: William P. Santamore, Jeanne M. Lesniak
-
Publication number: 20120094955Abstract: A method of dissolving an oxidized polysaccharide in an aqueous solution using an oligomer additive is described. The resulting aqueous solution of the oxidized polysaccharide may be used in combination with an aqueous solution comprising an amine-containing component to prepare hydrogel tissue adhesives and sealants for medical and veterinary applications, such as wound closure, supplementing or replacing sutures or staples in internal surgical procedures such as intestinal anastomosis and vascular anastomosis, tissue repair, ophthalmic procedures, drug delivery, and to prevent post-surgical adhesions.Type: ApplicationFiled: April 9, 2010Publication date: April 19, 2012Applicant: ACTAMAX SURGICAL MATERIALS LLCInventor: Mark E. Wagman
-
Patent number: 8153135Abstract: Disclosed is a method of producing a polysaccharide-polypeptide conjugate by reacting a polysaccharide with a polypeptide which contains at least one free amino group, wherein a polysaccharide carrier comprising vicinal hydroxyl groups is oxidized under ring opening to create vicinal aldehyde groups and is reacted with one or more base-instable antigenic polypeptide(s) containing at least one free amino group, the polypeptide(s) being bound directly to the polysaccharide carrier via at least one azomethine bond.Type: GrantFiled: September 13, 2005Date of Patent: April 10, 2012Inventors: Hans Loibner, Helmut Eckert
-
Publication number: 20120083466Abstract: Provided herein are methods of treating, suppressing, inhibiting, or preventing allergic rhinitis in a subject comprising the step of administering to a subject a compound comprising a lipid or phospholipid moiety bond to a physiologically acceptable monomer, dimer, oligomer, or polymer, and/or a pharmaceutically acceptable salt or a pharmaceutical product thereof.Type: ApplicationFiled: December 12, 2011Publication date: April 5, 2012Inventor: Saul YEDGAR
-
Publication number: 20120077773Abstract: A composition having an ionic complex of chitosan and a negatively charged polysaccharide, selected from the group consisting of heparin, heparan sulfate and dextran sulfate, for use in the treatment of mucositis in a mammalian subject, to a method of preventing or treating mucositis in a mammalian subject, by applying topically a composition having an ionic complex of chitosan and a negatively charged polysaccharide, selected from the group consisting of heparin, heparan sulfate and dextran sulfate. The composition further relates to a pharmaceutical composition for topical administration of an ionic complex of chitosan and heparin.Type: ApplicationFiled: June 10, 2010Publication date: March 29, 2012Applicant: EXTHERA ABInventors: Lars Adolfsson, Olle Larm, Anders Westermark
-
Publication number: 20120052042Abstract: The present disclosure relates to amphiphilic compounds, self assembling compositions formed from the amphiphilic compounds and methods of making such compositions.Type: ApplicationFiled: February 22, 2010Publication date: March 1, 2012Inventors: Sébastien Ladet, Philippe Gravagna
-
Publication number: 20120040928Abstract: A method for inhibiting cellular proliferation of fibroblasts and/or blioma cells in a mammal includes administering a composition to a mammal wherein the composition includes an amount of an anionic polymer and an anti-platelet agent effective to inhibit cellular proliferation of fi- broblasts and gliomas in the mammalType: ApplicationFiled: February 17, 2010Publication date: February 16, 2012Inventor: Rekha Bansal
-
Publication number: 20120035129Abstract: A hydrogel tissue adhesive having decreased degradation time is described. The hydrogel tissue adhesive is formed by reacting an oxidized polysaccharide with a water-dispersible, multi-arm polyether amine in the presence of an oligomer additive, which promotes the degradation of the hydrogel. The hydrogel may be useful as a tissue adhesive or sealant for medical applications, such as a hemostat sealant or to prevent undesired tissue-to-tissue adhesions resulting from trauma or surgery.Type: ApplicationFiled: April 9, 2010Publication date: February 9, 2012Applicant: ACTAMAX SURGICAL MATERIALS LLCInventor: Mark E. Wagman
-
Publication number: 20120014907Abstract: Disclosed are methods and compositions for the treatment of hyperlipidemia and conditions associated therewith, such as CHD, ischemic stroke, restenosis after angioplasty, peripheral vascular disease, intermittent claudication, myocardial infarction (e.g. necrosis and apoptosis), dyslipidemia and post-prandial lipemia. The methods include administration of a therapeutically effective amount of a compound of formula (I), wherein R is substituted adamantly; and N is 0 to 3; in free form or in acid addition salt form, and a pharmaceutically acceptable carrier.Type: ApplicationFiled: September 26, 2011Publication date: January 19, 2012Inventors: David Grenville Holmes, Thomas E. Hughes
-
Patent number: 8080254Abstract: The present invention relates to Fc-OB fusion protein compositions, methods of preparation of such compositions and uses thereof. In particular, the present invention relates to a genetic or chemical fusion protein comprising the Fc immunoglobulin region, derivative or analog fused to the N-terminal portion of the OB protein, derivative or analog.Type: GrantFiled: September 22, 2006Date of Patent: December 20, 2011Assignee: Amgen, Inc.Inventors: Michael B. Mann, Randy Ira Hecht, Mary Ann Pellymounter, Christopher Francis Toombs
-
Publication number: 20110293689Abstract: The present invention relates to immobilized biologically active entities having heparin cofactor II binding activity.Type: ApplicationFiled: August 11, 2011Publication date: December 1, 2011Inventors: Robert L. Cleek, Michael D. Daly, Krzysztof R. Pietrzak
-
Publication number: 20110280825Abstract: The invention features extracorporeal methods for the treatment of a subject having a pregnancy related hypertensive disorder, such as pre-eclampsia or eclampsia. The invention also features devices used for the extracorporeal treatment of subjects have a pregnancy related hypertensive disorder, such as pre-eclampsia or eclampsia.Type: ApplicationFiled: May 13, 2011Publication date: November 17, 2011Applicant: Beth Israel Deaconess Medical CenterInventor: S. Ananth Karumanchi
-
Publication number: 20110262442Abstract: The present invention provides combination therapies for treating a disease, disorder, or condition, and methods thereof.Type: ApplicationFiled: November 8, 2010Publication date: October 27, 2011Applicant: Adenios, Inc.Inventors: Charles P. Hamilton, Nathan Dean Jorgensen
-
Publication number: 20110243881Abstract: A process for treating fibroses including administering a therapeutically effective amount of a pharmaceutical composition which includes at least one biocompatible polymer of the following general formula (I): AaXxYy wherein: A represents a monomer selected from the group consisting of a sugar or —(O—CH2—CH2—CO)—, X represents a carboxyl group bonded to monomer A and is contained within a group according to the following formula: —R—COO—R?, in which R is a bond or an aliphatic hydrocarbon chain, optionally branched and/or unsaturated, and which can contain one or more aromatic rings except for benzylamine and benzylamine sulfonate, and R? represents a hydrogen atom or a cation, Y represents a sulfate or sulfonate group bonded to monomer A and is contained within a group according to one of the following formulas: —R—O—SO3—R?, —R—N—SO3—R?, —R—SO3—R?, in which R is a bond or an aliphatic hydrocarbon chain, optionally branched and/or unsaturated, and which can contain one or more aromatic rings except for benzyType: ApplicationFiled: June 14, 2011Publication date: October 6, 2011Inventors: Denis Barritault, Jean-Pierre Caruelle
-
Publication number: 20110224724Abstract: A hydrogel tissue adhesive formed by reacting an aminated polysaccharide with a water-dispersible, aldehyde-functionalized multi-arm polyether is described. The hydrogel tissue adhesive may be useful as a general tissue adhesive and sealant for medical and veterinary applications such as wound closure, supplementing or replacing sutures or staples in internal surgical procedures such as intestinal anastomosis and vascular anastomosis, tissue repair, ophthalmic procedures, drug delivery, and to prevent post-surgical adhesions. Additionally, due to the presence of the aminated polysaccharide, the hydrogel tissue adhesive may also promote wound healing and blood coagulation, and provide antimicrobial properties.Type: ApplicationFiled: August 31, 2009Publication date: September 15, 2011Inventors: Helen S.M. Lu, Steven Willis Shuey
-
Publication number: 20110217249Abstract: The present invention provides compositions containing one or more antimicrobial peptide sequestering compounds and methods for topical application of such compositions to the skin to treat skin diseases and disorders such as rosacea in humans.Type: ApplicationFiled: March 2, 2011Publication date: September 8, 2011Inventor: Frank Dreher
-
Publication number: 20110217339Abstract: The present invention relates to pharmaceutical compositions which are useful in the treatment of diseases where excess mucus is present in the respiratory tract, such as cystic fibrosis and chronic obstructive pulmonary disease. In particular, the invention relates to pharmaceutical compositions for administration by pulmonary inhalation.Type: ApplicationFiled: March 8, 2011Publication date: September 8, 2011Applicant: Vectura LimitedInventors: David MORTON, David GANDERTON, John STANIFORTH, Yorick KAMLAG
-
Publication number: 20110212045Abstract: Topical compositions for reducing the appearance of fine lines and wrinkles on the skin contain one or more ion exchange polymers, in a cosmetically or pharmaceutically acceptable carrier.Type: ApplicationFiled: August 31, 2010Publication date: September 1, 2011Inventors: Vasile Ionita-Manzatu, Thomas Mammone, Lavinia C. Popescu, Geoffrey Hawkins, Barbara Anne Wolf, Jack Lombardi
-
Publication number: 20110195928Abstract: The present invention is directed to the administration of copper to an animal using a composition containing copper dextran. A method is described for increasing the copper levels in an animal by the administration of a composition containing copper dextran. A preferred method of administration is intra muscularly. The use of this composition has been found to both address copper deficiencies in an animal, particularly deer.Type: ApplicationFiled: February 24, 2011Publication date: August 11, 2011Inventors: Wayne Leech, Donald George McLaren, Keith David McSporran
-
Publication number: 20110182987Abstract: This invention relates to a pharmaceutical dosage form for the site specific delivery of more than one active pharmaceutical ingredient to different sites in the human or animal body in the gastrointestinal tract. The dosage form has an outer polymeric layer incorporating a first active pharmaceutical ingredient which reacts to stimuli specific in the stomach, degrades, and releases the first active pharmaceutical ingredient in the stomach for absorption. The dosage form also has at least one inner polymeric layer incorporating a second active pharmaceutical ingredient which, once the outer layer has degraded, passes into the intestine where the polymers of the second layer degrade to release the second active pharmaceutical ingredient. The dosage form may have additional layers each incorporating active pharmaceutical ingredients for release in different portions of the intestine depending on the nature of the polymers.Type: ApplicationFiled: June 3, 2009Publication date: July 28, 2011Inventors: Priya Bawa, Viness Pillay, Yahya Choonara
-
Publication number: 20110158932Abstract: Methods and compositions containing a berberine compound or berberine related or derivative compound are provided for the prevention and treatment of hyperlipidemia, elevated cholesterol, and/or cardiovascular disease in mammalian subjects. The methods and compositions of the invention are effective for prevention and treatment of atherosclerosis, coronary artery disease, angina pectoris, carotid artery disease, stroke, cerebral arteriosclerosis, high blood pressure, myocardial infarction, cerebral infarction, restenosis following balloon angioplasty, intermittent claudication, dyslipidemia post-prandial lipidemia or xanthoma.Type: ApplicationFiled: December 8, 2008Publication date: June 30, 2011Inventors: Jian-Dong Jiang, Jing Wei, Wei-Jia Kong, Li-Xun Zhao, Dan-Qing Song
-
Publication number: 20110144054Abstract: Pharmacological compositions, and methods for administration, of the type employing an iron oxide complex with a polyol or polyether. The methods of administration may comprise parenteral administration of an effective dose of the complex formulated in a biocompatible liquid delivered at a rate of from about 1 mL/sec to less than 1 mL/min and wherein upon administration the complex provides minimal detectable free iron in a subject, and minimal incidence of anaphylaxis. The pharmacological compositions are of the type employing a polyol or polyether iron oxide complex, which, upon parenteral administration to a subject, are substantially immunosilent, provide minimal anaphylaxis and minimal free iron, and undergo minimal dissolution in vivo.Type: ApplicationFiled: December 8, 2010Publication date: June 16, 2011Applicant: AMAG PHARMACEUTICALS, INC.Inventors: Ernest V. Groman, Kenneth G. Paul, Timothy B. Frigo, Howard Bengele, Jerome M. Lewis
-
Publication number: 20110142941Abstract: Disclosed are methods of treating subjects having conditions related to angiogenesis including administering an effective amount of a polymeric Nanoparticle form of thyroid hormone agonist, partial agonist or an antagonist thereof, to promote or inhibit angiogenesis in the subject. Compositions of the polymeric forms of thyroid hormone, or thyroid hormone analogs, are also disclosed.Type: ApplicationFiled: November 16, 2010Publication date: June 16, 2011Inventors: Paul J. Davis, Shaker A. Mousa
-
Publication number: 20110129433Abstract: Disclosed herein are novel compositions and methods for treating or preventing GI tract disorders and/or GERD-related respiratory disorders as well as protecting stratified squamous epithelium against injury by a noxious substance. The methods generally include administering to a patient in need thereof a therapeutically effective amount of a pharmaceutical composition comprising at least one bile acid sequestrant, alone or in combination with at least one proton pump inhibitor, and optionally one or more agent chosen from antacids, histamine H2-receptor antagonists, ?-aminobutyricacid-b (GABA-B) agonists, prodrugs of GABA-B agonists, and protease inhibitors.Type: ApplicationFiled: June 26, 2009Publication date: June 2, 2011Applicant: IRONWOOD PHARMACEUTICALS, INC.Inventor: Mark G. Currie
-
Publication number: 20110118207Abstract: The present invention is related to a modified hydroxypolymer conjugate, preferably a dextran-guanidine-biphosphonate conjugate for treating not only skeletal tumors i.e. bone metastasis, particularly bone metastasis related to hormone refractory prostate cancer HRPC and breast cancer, but also osteoporosis. A method for producing and using said hydroxypolymer conjugate is also disclosed.Type: ApplicationFiled: April 7, 2008Publication date: May 19, 2011Applicant: DEXTECH MEDICAL ABInventor: Anders Holmberg
-
Publication number: 20110110868Abstract: The present disclosure provides compositions comprising 2-deoxyglucose-functionalized magnetic nanoparticles. The compositions are useful in various applications, which are also provided.Type: ApplicationFiled: April 1, 2009Publication date: May 12, 2011Inventors: Massoud Akhtari, Jerome Engel
-
Publication number: 20110081418Abstract: An object of the present invention is to provide a transdermal absorption enhancer by which various active ingredients are transdermally absorbed. In accordance with a transdermal absorption enhancer of the present invention which effective ingredient is lyotropic liquid crystal which has been utilized as a basic material for pharmaceutical preparations for external application and for cosmetics, transdermal absorption of a macromolecular substance and a water-soluble substance was able to be improved.Type: ApplicationFiled: September 7, 2010Publication date: April 7, 2011Applicants: JAPAN SCIENCE AND TECHNOLOGY AGENCY, NANOEGG RESEARCH LABORATORIES, INC.Inventors: Yoko Yamaguchi, Rie Igarashi
-
Patent number: 7902174Abstract: Chemical compounds, being the alkyl sulfate of sulfated saccharides, particularly, dextrin, dextran, and cyclodextrin, and pharmaceutical compositions containing these compounds. The compounds of the invention provide antiviral activity, particularly in the treatment and prevention of sexually-transmitted diseases. Methods of treating viral infection and preventing viral transmission include administration include administration of the compounds of the invention orally, topically, subcutaneously, by muscular injection, by intraperitoneal injection and by intravenous injection.Type: GrantFiled: February 6, 2009Date of Patent: March 8, 2011Inventor: Roger Hershline
-
Publication number: 20110052732Abstract: A mineral absorption accelerator, and an anemia improving agent, food and drink or food and drink material containing the mineral absorption accelerator are provided, the mineral absorption accelerator including: an ?-glucosidase inhibitory component.Type: ApplicationFiled: April 3, 2009Publication date: March 3, 2011Applicant: FUJIFILM CorporationInventor: Fumitaka Ueda